Kornimate/medical-research-clean huggingface dataset:
textbook outcomes of right hemihepatectomy in patients with hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Hepatectomy; Laparoscopic Hepatectomy

Summary: although traditional open right hemihepatectomy is a mature technique, the incision is usually very large; intraoperative bleeding may be excessive, and postoperative liver failure is also prone to occur. in recent years, compared with traditional open surgery, laparoscopic surgery has many advantages, such as smaller surgical incision and faster postoperative recovery. in recent years, more and more centers have gradually transitioned to performing right hemihepatectomy through laparoscopy as much as possible. however, due to the difficulty of the surgery, steep learning curve, and postoperative complications, its adoption is limited to high-capacity surgical centers. despite significant progress in laparoscopic liver resection technology, its clinical efficacy remains controversial, especially in laparoscopic right hemihepatectomy. more research is needed to confirm the feasibility and safety of this surgery. at present, it is unclear whether there is a difference in textbook outcomes (to) between hcc patients undergoing open and laparoscopic right hemihepatectomy, and the association between to and patient survival prognosis.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old; 2. the lesion is limited to the right half of the liver and diagnosed as hepatocellular carcinoma based on paraffin pathology and immunohistochemistry results; 3. the type of surgery is elective surgery; 4. the patient's preoperative liver function was child pugh a or b grade, and the preoperative asa (american society of anesthesiologists) rating was i, ii, or iii. exclusion criteria: 1. pathological confirmed cholangiocarcinoma, mixed cell carcinoma, or extrahepatic metastatic malignant tumors; 2. previous history of upper abdominal surgery; 3. simultaneously undergoing adjacent abdominal organ resection, major vessel and biliary reconstruction surgery, except for the gallbladder; 4. merge adjacent organ invasions except for the gallbladder, with main blood vessels, bile duct cancer emboli, or distant metastases; 5. lost to follow-up or loss of primary clinical data.
self-reports of executive functions in persons with parkinson's disease and their significant others

Conditions: Parkinsonism or Parkinson's Disease Nos

Summary: the investigators are conducting a study to compare the self-reports of executive functions (that is to say, what role cognitive processes such as working memory and attention) in persons with parkinson's disease to the reports of executive functions completed by their significant others. to conduct this study, the investigators need the participation of persons who are diagnosed with parkinson's disease and their significant others.

the purpose of this study is to explore the relationship between the self-reported executive functions (efs) in persons with parkinsons disease (pd) and their significant others. executive functions include basic cognitive processes such as attention, inhibition, working memory, and cognitive flexibility. as this proposed study will test not only cognitive functioning, but specific aspects of it (i.e., efs) without excluding persons with pd who have identified cognitive impairments, outcomes gathered could provide valuable information to better assist all types of persons with pd. comparing their self-reported efs to the ef ratings completedy by their signifiant others can help determine if a disparity exists between self-perceptions and actual observed ef abilties. this study would assess efs through inhibition responses of participants via computerized versions the comprehensive executive function inventory-adult self-report and observer forms.

Eligibility criteria:
inclusion criteria: * for persons with pd,confirmed diagnosis of pd) for significant others - relationship with person with pd exclusion criteria:all participants will be screened to ensure they do not have: * any known cognitive disorders other than those associated with pd * impairments in vision that would affect their ability to safely participate in the study * recent history of neuromuscular injury/ damage that could affect their ability to complete the cefi * the participant will be excluded if he or she is unable to follow commands well enough to complete the cefi
the effect of preoperational hand massage anxiety level and hemodynamic variables

Conditions: Anxiety; Hemodynamic Instability

Summary: the study was conducted randomly controlled experimental to determine the effect of hand massage applied to pre-operative children on anxiety level and physical symptoms of anxiety.

on operation morning, "child and parent introduction form", "state-trait anxiety inventory for children" were read to and "physiological symptoms of anxiety inspection form" measurement was done on children in both groups, and their 1st measurement values were recorded. routine treatment and nursing care applications of the service were done preoperationally. after the researcher and the children in study group sat on a chair facing each other, hand massage procedure, 8 minutes to both hands and a total of 16 minutes hand massage was applied with liquid petrolatum. no massage was applied to children in control group. right 16 minutes after the 1st filled forms in each group, "state-trait anxiety inventory for children", "physiological symptoms of anxiety inspection form" were read, measurement was done and 2nd measurement values were recorded. furthermore, "satisfaction evaluation scale" was marked by those in study group after the massage, and measurement values were recorded.

Eligibility criteria:
inclusion criteria: * agreeing to participate in the study and obtaining written permission from the family, * able to speak and understand turkish, * not taking any analgesic and anesthetic drugs before the procedure, * over 9 years old and under 12 years old, * whose parents are literate, * poor general condition and not needing emergency surgery (cases such as acute abdomen, intestinal perforations, traumas, etc.), * there is no open wound on the skin or an obstacle to massage (edema, abscess, skin infection with necrosis, etc.), * thrombophlebitis, occlusive artery disease, fever etc. who do not have a situation in which massage application is objectionable due to illness, he does not have conditions such as loss of sensation, mass, fracture and ingrown nails in his hand, * children who are conscious, fully oriented and cooperative and open to communication exclusion criteria: * those who do not accept to participate in the research and do not get written permission from their families, * does not speak or understand turkish * taking any analgesic and anesthetic drugs before the procedure, * less than 9 years old and over 12 years old, * illiterate parents * poor general condition and emergency surgery (acute abdomen, intestinal perforations, traumas, etc.) cases) need, * open wound on the skin or an obstacle to massage (edema, abscess, necrosis has occurred) skin infection etc.) * thrombophlebitis, occlusive artery disease, fever etc. massage practice due to illness having a situation where it is objectionable, * having conditions such as loss of sensation in the hand, mass, fracture and ingrown nails, * children who are unconscious, oriented and cooperative and not open to communication
effect of manual massage technique on swelling, pain and mouth opening after bilateral lower third molar surgery

Conditions: Impacted Third Molar Tooth; Swelling/ Edema; Pain; Trismus

Summary: the aim of this study was to evaluate the effect of manual lymphatic drainage on pain, edema and trismus after impacted mandibular third molar surgery.

this study is a randomized controlled split-mouth trial. a total of 46 healthy patients who presented to our department for the extraction of impacted mandibular third molars were included in this study.the inclusion criteria were as follows: presence of pericoronal infection, no recent use of anti-inflammatory medications, symmetrical impactions on both sides, asymptomatic cases, and class 2, position b or c, vertical and mesioangular impactions. impactions were classified using the pell and gregory classification system. exclusion criteria included patients who declined participation, pregnant or lactating individuals, patients with penicillin allergies, those with chronic diseases that could affect healing, uncooperative patients. following the surgery, manual lymphatic drainage therapy was administered in the afternoon of the same day by a professional physiotherapist using the "vodder" technique. in this study, measurements were conducted by two researchers. swelling and trismus values were recorded preoperatively (t0), on the 3rd postoperative day (t1), and on the 7th postoperative day (t2). to assess pain, the vas was used and values were recorded 1, 2, 3 and 7 days postoperatively. in this study, edema was evaluated using the 3dmd face system (3dmd, atlanta, ga), which virtually transfers the patient's face into 3d, allowing for the calculation of volume changes.to assess pain, the visual analog scale (vas) was used.to determine the effect of mld therapy on postoperative trismus, the distance between the upper and lower incisors was measured using a digital caliper immediately before the operation, as well as on the 3rd and 7th postoperative days

Eligibility criteria:
inclusion criteria: * good general health conditions; * presence of bilateral and symmetrical impacted third molars (according to the classifications of winter and pell and gregory); exclusion criteria: * no clinical evidence of major facial asymmetry; * use of medication that would influence or alter wound healing; * temporomandibular joint disorder history; * smoking

Keywords: impacted lower third molar 3dmd manual lymphatic drainage edema
attachment and prognostic factor: the implicit approach

Conditions: Dependence Addictive

Summary: this is a prospective longitudinal study aimed at better understanding the determinants of the prognosis of patients with substance dependence. 5 visits are planned during the study : * the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online * 4 telephone interviews for follow-up by investigator.


Eligibility criteria:
inclusion criteria: * patients between 18 and 65 years old * patients with a use-related disorder as defined by dsm5 * patients weaning for a substance, supported within the addictology sector of henri laborit hospital * having expressed non-opposition to participating in the study after receiving written information. exclusion criteria: * person who cannot read or write * simultaneous participation in a therapeutic trial involving oxytocin * patients protected by law * patients who do not have french as their native language * patients who, in the opinion of the investigator, are unable to complete the questionnaires

Keywords: implicit approach post-weaning prognostic factor
efficiency of budesonide combined with formoterol and tiotropium in the treatment of acute exacerbation of aco

Conditions: Asthma-COPD Overlap

Summary: this study evaluates the efficiency of ics(budesonide) combined with laba (formoterol) and lama(tiotropium) in the treatment of acute exacerbation of asthma-chronic obstructive pulmonary overlap. half of participants will receive budesonide,formoterol and tiotropium in combination, while the other half will receive budesonide and formoterol only.

aco(asthma-chronic obstructive pulmonary overlap) is a relatively new proposed clinical form of chronic airway disease. guideline or preferring therapy for aco is still evolving. current clinical solution is when aco presents like asthma, initial treatment will accord to the guideline for asthma , while it presents like copd, copd recommendation treatment (not alone ics,but ics in addition of laba with or without lama) will be chosen, which are subjective. although present guidelines has recommended that aco should be treated with at last two inhalant, but limited date have proven it. a random controlled trial will be conducted to evaluate the efficiency of ics(budesonide) combined with laba (formoterol) and lama(tiotropium bromide) in the treatment of acute exacerbation of aco,compared with the control group receiving tiotropium bromide with formoterol only.

Eligibility criteria:
inclusion criteria: * subject has aco exclusion criteria: * acute exacerbation of aco; * acute infection; * postbrochodilator fev1/fvc\> 0.7; * pulmonary complications: bronchiectasis, active tuberculosis, pulmonary fungal disease or lung cancer * history of other malignant tumor * with rheumatic diseases; * with some serious heart, cerebrovascular, liver, kidney or hematopoietic system diseases * with tachyarrhythmias； * mental patients; * with moderate to severe renal insufficiency (creatinine clearance ≤ 50ml / h) * allergic to the budesonide, formoterol or tiotropium bromide; * history of acute gastrointestinal bleeding within 3 months; * with severe angle closure glaucoma patients; * pregnancy,lactation; * have participated in other clinical trials in 3 months； * hospital staff and their relatives

Keywords: ics laba lama therapy asthma copd aco
study to assess the safety and pharmacokinetics of cy6463 in participants with stable schizophrenia

Conditions: Schizophrenia

Summary: the primary objective of this study is to evaluate the safety and tolerability of cy6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen


Eligibility criteria:
inclusion criteria: 1. provides written informed consent to participate in this study 2. body mass index is between 18 to 40 kg/m2 3. fluent english speaker 4. diagnosed with schizophrenia at least 1 year ago 5. psychiatrically stable schizophrenia with no more than moderate symptomatology 6. on a stable atypical antipsychotic regimen 7. agrees to use effective contraception throughout the study and for at least 3 months afterward 8. agrees to avoid using tobacco/nicotine and caffeine for several hours at a time 9. agrees to not participate in another study of a drug or device while in this study exclusion criteria: 1. was in another study of a drug in the past 2 months 2. fails a drug/alcohol screen, including amphetamines, barbiturates, cocaine, marijuana, methadone, methamphetamine, 3,4 methylenedioxymethamphetamine (mdma), phencyclidine, or nonprescribed benzodiazepines or opiates 3. has had a recent heavy smoking habit (\>40 cigarettes/2 packs/day) or recently had nicotine replacement therapy 4. has significant heart disease 5. has hemophilia or any other bleeding/platelet dysfunction condition 6. has hepatitis or hiv additional inclusion and exclusion criteria apply, per protocol.

Keywords: cognitive impairment associated with schizophrenia cias cy6463
a study of mitoxantrone hydrochloride liposome injection in the treatment of recurrent/metastatic head and neck cancers

Conditions: Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer

Summary: this is a multicenter, open-label, single-arm, phase ib study to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome in subjects with recurrent/metastatic head and neck cancers

this is a multicenter, open-label, single-arm, phase ib study to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome in subjects with recurrent/metastatic head and neck cancers. at least 30 subjects will be recruited in this study. the subjects will receive mitoxantrone hydrochloride liposome 20 mg/m2 by an intravenous infusion (iv), every 21 days (q3w, 1 cycle). all patients will receive the treatment until disease progression, intolerable toxic reaction, death, or withdrawa by investigator or patient decision (a maximum of 8 cycles). delays in drug administration is allowed from the cycle 2, however, the delays should be no more than 3 weeks. dose adjustments after the cycle 2 is permitted, and the minimum dose is 12mg/m2.

Eligibility criteria:
inclusion criteria: 1. subjects fully understand and voluntarily participate in this study and sign informed consent; 2. . age ≥18, female or male; 3. histologically confirmed diagnosis of head and neck squamous cell carcinoma (including nasopharyngeal carcinoma) 4. fail to respond to or progressed on at least one line of the standard therapy; 5. at least one measurable lesion according to recist v1.1; 6. ecog performance status of 0 to 1; 7. aes from the previous treatment have resolved to ≤ grade 1 based on exclusion criteria: 1. history of allergy to mitoxantrone hydrochloride or any excipients of the study drug; 2. untreated or symptomatic central nervous system (cns) metastases; 3. history of allotransplantation; 4. life expectancy \< 3 months 5. known hepatitis b virus (hbv), hepatitis c virus (hcv), human immunodeficiency virus (hiv) or other active viral infection; 6. serious infection or interstitial pneumonia within 1 week prior to the first dose administration; 7. use of other anticancer treatment within 4 weeks prior to the first dose administration; 8. enrolled in any other clinical trials within 4 weeks prior to the first dose administration; 9. major surgery within 3 months prior to the first dose administration, or have a surgical schedule during the study period; 10. thrombosis or thromboembolism within 6 months prior to screening; 11. history of, or known additional malignant tumor within 3 years, except for tumors have been cured and have not recurred, and carcinoma in situ; 12. impaired cardiac function or serious cardiac disease 13. previous treatment with adriamycin or other anthracyclines, and the total cumulative dose of prior adriamycin or equivalent is \>350 mg/m2 14. pregnant or lactating female; 15. serious and/or uncontrolled systemic diseases; 16. not suitable for this study as decided by the investigator due to other reasons.
men study (estudio men) quality of life in patients with bph and nocturia before and after tamsulosin ocas® treatment

Conditions: Prostatic Hyperplasia

Summary: this is an exploratory study, to evaluate the improvement in terms of quality of life that can be reached by a group of outpatients with bph ( benign prostatic hyperplasia ) and nocturia when they are under treatment with secotex ocas. this study will explore, the progress in terms of quality of life that can be reached by a group of outpatients with bph ( benign prostatic hyperplasia) and nocturia treated with secotex ocas®. this is a not controlled study, " before and after type", which will consist of an assessment, of the quality of life for outpatients with bph symptoms including nocturia, through the use of the spanish version of the nocturia quality-of-life (nqol) questionnaire, at three different moments: 1. before to start secotex ocas® treatment. 2. thirty (30) days after first visit and starting secotex ocas® treatment 3. ninethy (90) days after first visit and starting secotex ocas® treatment

study design:

Eligibility criteria:
inclusion criteria: men 40 years old with benign prostatic hyperplasia (bph) which, according their doctor, requires medical treatment to improve quality of life. patients may be new in the treatment or can be treated with other medicines but not having responded adequately to treatment (not should be taking tamsulosin ocas). psa \ 12 points. two or more episodes of nocturia per night (score equal or exceed 2 in question 7 of ipss). ipss qol (question 8) \> 3 points (score equal or superior to 3 in question 8 of quality of life (qol) of ipss). acceptance written of their participation in the study by the informed consent. the decision of treatment should be based on the best clinical practice accepted standard and according to the information for prescription for secotex ocas® 0.4 mg. exclusion criteria: patients with clear indication to receive surgical treatment hospitalized patients patients with physical or mental disabilities that prevent, even with the help of doctor, completing the instruments of assessment of the survey patients with a history of malignant disease patients with known hypersensitivity to tamsulosin or to another component of the product patients with a history of orthostatic hypotension or severe liver failure positive digital rectal test for possible neoplasia or biochemical evidence of high psa with figures \> 4.0 ng/ml patients with diastolic blood pressure less than 60 mmhg or tachycardia greater to 120 beats per minute other reasons for the exclusion: * acute urinary retention (aur) * urinary tract infection * renal failure
18f-fdg pet/ct to evaluate pd-1 monoclonal antibody with first-line chemotherapy in advanced nsclc

Conditions: NSCLC

Summary: this study is a diagnostic study. subjects were enrolled from clinical stage iiib or iv nsclc patients who received standard first-line chemotherapy combined with pd-1 monoclonal antibody immunotherapy and received 18f-fdg pet/ct imaging before treatment, after 2 courses of treatment, and at the time of disease progression.at the same time, the blood routine, liver and kidney function, inflammatory indexes and other laboratory data of the subjects participating in the study were collected. based on 18f-fdg pet ipercist standard and comprehensive laboratory indicators, the subjects were evaluated for tumor biological characteristics prediction and clinical staging, pd-1 immune efficacy monitoring and evaluation, tumor recurrence monitoring and re-staging. at the same time, the systemic immune response and immune-related adverse events during the treatment process were evaluated in order to establish a better evaluation standard and system for the comprehensive evaluation of pd-1 immunotherapy.this study plans to set the sample size as 50 cases.

this is a diagnostic study. subjects were enrolled from clinical stage iiib or iv nsclc patients who received standard first-line chemotherapy combined with pd-1 monoclonal antibody immunotherapy and underwent 18f-fdg pet/ct imaging before treatment, after two lines of treatment and at the time of disease progression, while routine blood counts, liver and kidney function, inflammatory indices and other laboratory data were collected from subjects enrolled in the study. based on standard 18f-fdg pet ipercist and comprehensive laboratory indicators, subjects were evaluated for prediction of tumour biological characteristics and clinical staging, monitoring and evaluation of pd-1 immune efficacy, monitoring of tumour recurrence and restaging. at the same time, the systemic immune response and immune-related adverse events during the treatment process were evaluated to establish a better evaluation standard and system for the comprehensive evaluation of pd-1 immunotherapy.

Eligibility criteria:
inclusion criteria: * adult patients (age 18 or above), gender unlimited; * pathological diagnosis of non-small cell lung cancer stage iiib or above; * agree to carry out the standard first-line chemotherapy combined with immunosuppression established in this study; * consent to 18f-fdg pet/ct imaging and related laboratory examination before and during treatment; * the patients themselves or their legal representatives are aware of this study and can sign the informed consent. exclusion criteria: * acute systemic diseases and electrolyte disturbances; * pregnant or lactating women; * the patient or his legal representative is unable or unwilling to sign the informed consent.